This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thom J. Zimmerman, MD, PhD; Robert D. Fechtner, MD

Arch Ophthalmol. 1997;115(12):1579-1580.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

NOT TOO LONG AGO, maximal tolerated medical therapy (MTMT) for glaucoma usually meant a β-blocker, a cholinergic agent (usually pilocarpine or carbachol), and an oral carbonic anhydrase inhibitor (CAI) (usually diamox or neptazane). Sometimes epinephrine or dipivefrin was added to the regimen. Prescribing MTMT for an individual patient depended on whether or not that patient could tolerate any or all of this regimen. With MTMT compliance was always suspect, not just because of the side effects of these drugs, especially the cholinergic agents and the CAIs, but also because of the difficult dosing schedules. At worst, a patient would be taking 4 pills and 6 to 8 drops in each eye daily. The morning and evening dosing could take 15 minutes under the best conditions (the patient applying bilateral nasolacrimal occlusion while a family member administered drops to both eyes every 5 minutes). This would be difficult to tolerate even . . . [Full Text PDF of this Article]

Author Affiliations
Louisville, Ky

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?